Last update 27 Jul 2026

Catalent CTS LLC

Subsidiary Company|2004|New Jersey, United States|
www.catalent.com

Overview

Basic Info

Introduction
Catalent CTS LLC is a US-based organization that focuses on developing pharmaceutical formulations. It is a division of Catalent, Inc.

Tags

Hemic and Lymphatic Diseases
Neoplasms
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Endocrinology and Metabolic Disease2
Nervous System Diseases1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
ACADS x XPO11
MTTP(Microsomal triglyceride transfer protein)1

Related

2
Drugs associated with Catalent CTS LLC
Selinexor
Target
ACADS x XPO1
Mechanism
ACADS inhibitors [+1]
Active Org.
Antengene Corp. Ltd.Antengene Corp. Ltd. [+15]
Originator Org.
Karyopharm Therapeutics, Inc.Karyopharm Therapeutics, Inc.
Active Indication
Follicular Lymphoma [+70]
Inactive Indication
Acute Myeloid Leukemia with FLT3/ITD Mutation [+69]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date03 Jul 2019
Lomitapide Mesylate
Target
MTTP
Mechanism
MTTP inhibitors
Active Org.
University of PennsylvaniaUniversity of Pennsylvania [+7]
Originator Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Indication
Hyperlipidemia Type IIa [+2]
Inactive Indication
Familial chylomicronaemia syndrome
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date21 Dec 2012
8
Clinical Trials associated with Catalent CTS LLC
CTR20260924
/ RecruitingPhase 1
一项在中国健康参与者中评估EVO756的安全性、耐受性和药代动力学的单剂量和多剂量递增研究
[Translation] A single-dose and multiple-dose escalation study evaluating the safety, tolerability, and pharmacokinetics of EVO756 in healthy Chinese participants.
CTR20240163
/ CompletedPhase 1
一项旨在评价JNJ-67953964在健康中国成人受试者中的药代动力学、安全性和耐受性的开放性、多次给药研究
[Translation] An open-label, multiple-dose study to evaluate the pharmacokinetics, safety, and tolerability of JNJ-67953964 in healthy Chinese adult subjects
CTR20230821
/ Active, not recruitingPhase 3
一项在既往未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者（无TP53畸变）中比较MK-1026与化学免疫疗法的有效性和安全性的III期、随机研究（BELLWAVE-008）
[Translation] A Phase III, randomized study comparing the efficacy and safety of MK-1026 with chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma without TP53 aberrations (BELLWAVE-008)
100 Clinical Results associated with Catalent CTS LLC
Login to view more data
0 Patents (Medical) associated with Catalent CTS LLC
Login to view more data
100 Deals associated with Catalent CTS LLC
Login to view more data
100 Translational Medicine associated with Catalent CTS LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 Jul 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
2
2
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free